← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Big Eye Diagnostics, Inc.
San Diego, CA
$5,835,895
Total funding
6
Grants
Funding over time
peak $2.9M · FY2022–25$5M$3.8M$2.5M$1.3M$0
'22
'23
'24
'25
Funding mix
By agency
NIH$5,835,895 · 6
By mechanism
R44$4,978,079 · 3
N01$299,986 · 1
N43$299,659 · 1
R43$258,171 · 1
Investigators at Big Eye Diagnostics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS$921,480
R44 · FY2023 · AI
SUPPORTING WHO ONCHOCERCIASIS ELIMINATION PROGRAMS: PROGRESSING A HIGHLY SENSITIVE AND ULTRA-SPECIFIC RAPID DIAGNOSTIC TEST TO COMMERCIALIZATION READINESS$908,264
R44 · FY2024 · AI
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$852,688
R44 · FY2024 · AI
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$842,379
R44 · FY2025 · AI
Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness$797,183
R44 · FY2024 · AI
Supporting WHO Lymphatic Filariasis Elimination Programs: Progressing a Highly Sensitive and Specific Rapid Diagnostic Test for Brugia Species Infection to Commercialization Readiness$396,523
R44 · FY2025 · AI
NOVEL DIAGNOSTIC BIOMARKERS DISCOVERY AND VALIDATION FOR SELECT NEGLECTED TROPICAL DISEASES$299,986
N01 · FY2025 · AI
An Easy-to-Use, Low-Cost Triplex RDT for the Simultaneous Diagnosis of HBV, HCV, AND HIV Infection, Compatible with Field Use in LMICS and At-Home Use in the US$299,659
N43 · FY2024 · AI
Ultrasensitive, High-Specificity Rapid Test to Support the End-Game of the Global Program to Eliminate Lymphatic Filariasis$259,562
R44 · FY2022 · AI
First-in-class, highly sensitive and specific rapid diagnostic test to detect Paragonimus infections$258,171
R43 · FY2022 · AI